CagriSema Tracker App for Side Effects, Food, and Weight
MeAgain is a CagriSema tracker for the record you can build now: current medication, shot day, side effects, food, water, and weight trend. CagriSema combines cagrilintide and semaglutide in one weekly pen, which is why people describe it as two drugs in one pen rather than a single new molecule. As of July 2026, CagriSema is not FDA-approved. Novo Nordisk submitted an FDA application in December 2025 and has guided to a possible decision in late 2026, but that is company guidance, not a confirmed FDA date. While waiting or taking part in a Novo study, the useful habit is still simple: track what you are currently using, record stomach and digestion symptoms, keep food and water visible, and follow the long weight trend. If a new medication arrives later, your MeAgain history carries over. 421K users already use MeAgain, with 4.8 stars across 21K App Store ratings.
Key takeaways
CagriSema is best described as two drugs in one weekly pen: cagrilintide plus semaglutide. That matters for tracking because the routine still looks familiar day to day: shot day, side effects, meals, water, and the long weight trend.
CagriSema has no FDA approval as of July 2026. Novo filed its application in December 2025 and points investors to a possible late-2026 decision - guidance, not a scheduled date.
The pivotal REDEFINE results are the main reason people are searching CagriSema. REDEFINE 1 reported 22.7% mean weight loss in adults without diabetes, while REDEFINE 2 reported 13.7% in adults with type 2 diabetes. Both were published in NEJM.
CagriSema did not beat Zepbound in the REDEFINE 4 head-to-head trial. Novo reported 23.0% weight loss for CagriSema versus 25.5% for Zepbound, and the trial did not meet its primary goal.
MeAgain is useful now because the tracking habit does not have to wait for approval. Track your current medication, side effects, food, water, and weight trend; if a new medication arrives later, that history carries over.
What Makes MeAgain the Right CagriSema Tracker?
01A Weekly Shot Log for the Routine Around CagriSema
CagriSema is not publicly available yet, but the weekly routine people want to understand is already clear enough to track. MeAgain lets you save the medication you are using now, the date and time of each shot, and the shot site on a body diagram. That makes the record useful whether you are following CagriSema research, taking part in a Novo study, or using another weekly GLP-1 while you wait. The important part is continuity. If your medication changes later, your shot history, side effect notes, food logs, and weight trend stay in one place instead of starting over from a blank timeline. It also gives you cleaner context for appointments because the week is recorded as it happened, not reconstructed from memory.
02Side Effect Tracking for Stomach and Digestion Symptoms
Novo described CagriSema side effects in the pivotal trials as mainly stomach and digestion problems, including nausea, vomiting, diarrhea, and constipation. MeAgain turns that broad list into a week-by-week record. You can log common GLP-1 side effects, add custom symptoms, score how strong they felt, and attach notes about meals, hydration, or timing. That matters because a symptom that feels random in the moment can make more sense when it sits next to shot day, a low-food day, or a change in routine. If you are in a study, that kind of clean symptom timeline is also easier to discuss with a clinician than a few scattered notes. The goal is not to guess what caused a symptom; it is to keep the pattern visible.
03Food, Water, and Weight Trends While You Wait
CagriSema headlines focus on trial percentages, but the day-to-day work is smaller: eating enough protein, drinking enough water, and not overreacting to one weigh-in. MeAgain keeps meals, water, side effects, and weight in the same timeline so you can see what happened before a rough day or a surprising scale change. Food logging is built to stay quick with photo scan, barcode scan, voice dictation, text search, and quick-add for repeat meals. The weight chart keeps the long view visible, which is the part that matters most for medications studied over many months. That longer view is also useful while waiting because your current habits become the baseline for any future change. It keeps current-med context beside the future CagriSema question.
04A History That Carries Over if New Meds Arrive
The strongest reason to start tracking before CagriSema approval is that your history becomes more valuable over time. If you are using semaglutide, tirzepatide, or another current medication today, MeAgain can keep the same practical record CagriSema would need later: current medication, shot dates, side effects, meals, water, and weight. When new medications reach real-world use, the question is rarely just which name is on the box. It is what changed in your routine, symptoms, appetite, and trend. A continuous MeAgain timeline gives you that before-and-after view without asking you to rebuild your records. It also keeps the waiting period productive because each week adds context instead of another loose note. That continuity is the point of tracking before approval.
What to Know About CagriSema Availability and Tracking
CagriSema remains experimental and trial-only as of July 2026. The FDA application, filed in December 2025, rests on REDEFINE 1 and REDEFINE 2; Novo's own investor guidance points to a possible decision in late 2026, and no confirmed FDA date exists. The main published trial results are REDEFINE 1, which reported 22.7% mean weight loss over 68 weeks in adults without diabetes, and REDEFINE 2, which reported 13.7% over 68 weeks in adults with type 2 diabetes. If you compare CagriSema with Zepbound, the plain fact is that REDEFINE 4 reported CagriSema 23.0% versus Zepbound 25.5%, and CagriSema did not meet its head-to-head goal. MeAgain gives you the tracker for the part you can use now: current medication, side effects, food, water, and the long weight trend.
| CagriSema | Tirzepatide / Zepbound | Semaglutide / Wegovy | |
|---|---|---|---|
| Current U.S. status | Trial-only, not FDA-approved | FDA-approved | FDA-approved |
| How often taken | Weekly pen | Weekly shot | Weekly shot |
| Sourced trial weight results | 22.7% in REDEFINE 1; 13.7% in REDEFINE 2 | 20.9% in 72 weeks (SURMOUNT-1) | 14.9% in 68 weeks (STEP-1) |
| Head-to-head context | Lost REDEFINE 4: 23.0% vs 25.5% for Zepbound | 25.5% in REDEFINE 4 | No CagriSema head-to-head result on this page |
| What MeAgain helps you track | Current med, side effects, food, weight trend | Current med, side effects, food, weight trend | Current med, side effects, food, weight trend |
CagriSema Facts to Know Right Now
- As of July 2026, CagriSema is not FDA-approved and is not publicly available
- CagriSema combines cagrilintide and semaglutide in one weekly pen
- Novo Nordisk submitted the FDA application in December 2025
- Novo guidance points to a possible late-2026 FDA decision, not a confirmed FDA date
- REDEFINE 1 reported 22.7% mean weight loss over 68 weeks
- REDEFINE 2 reported 13.7% mean weight loss over 68 weeks in adults with type 2 diabetes
- REDEFINE 4 reported CagriSema 23.0% versus Zepbound 25.5%, so do not frame CagriSema as the head-to-head winner
- The tracker basics stay simple: current medication, side effects, food, water, and weight trend
CagriSema may still be trial-only, but the habits around GLP-1 tracking are useful now. MeAgain keeps your current medication, shot history, side effects, food, water, and weight trend in one place so the record is ready if your medication changes later.
This content is for informational purposes only and does not constitute medical advice. As of July 2026, CagriSema is experimental, in clinical trials, and not FDA-approved for any use. Published CagriSema results may change as more Phase 3 data are released. Always talk with a licensed clinician about CagriSema, weekly GLP-1 treatment, or weight-management medication. MeAgain is not affiliated with Novo Nordisk and does not enroll people in CagriSema trials.
Sources
- Novo Nordisk - FDA filing for CagriSema for chronic weight management (December 2025)
- NEJM - CagriSema in Adults with Overweight or Obesity (REDEFINE 1 and 2, June 2025)
- Novo Nordisk - REDEFINE program investor materials
- Novo Nordisk - REDEFINE 4 head-to-head CagriSema and Zepbound results (February 23, 2026)
- Jastreboff AM et al. - Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, NEJM 2022, n=2,539)
- Wilding JPH et al. - Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1, NEJM 2021, n=1,961)
What MeAgain Users Track Before New Meds Arrive
Why People Use MeAgain While CagriSema Is Still Trial-Only
As of July 2026, CagriSema is not publicly available, so there are no CagriSema-specific App Store reviews. The tracking pattern a weekly pen would need is already visible in how people use the app today. One reviewer (carmelavant, June 15, 2026) put it this way:
Loving this app it keeps me accountable during my journey highly recommend & keep track of everything
- shot day, meals, water, and reminders in one record. That is the same structure a CagriSema routine would use if it reaches the public later, and it is what people in a study or on a current weekly GLP-1 track now.
MeAgain keeps the record focused on what can be tracked today: current medication, side effects, meals, water, and weight trend. For anyone waiting on CagriSema news, that means the tracking habit does not depend on the approval timeline. If your medication changes later, the history you already built still gives you a clearer before-and-after view.
What Our Users Say
“I've been using the app for about 7 months now and I love how I'm able to track my meals and my daily medication. The little capybara widget is a great visual to help me know what my body needs.”
“This app does exactly what I needed with tracking shots… location, time, amount, current medication level, and reminders for the next one. That plus weight progress is all I needed, and after trying at least 5 others this was the only one that did it in a clean, logical way- and didn't cost a fortune!”
“I really love this app and how easy it is to use for my food, water, Mounjaro weekly shot and everything else. The app is totally worth the cost and it's been perfect for me.”
“I've been on my MJ journey since September 2025. Seeing my food intake has made a huge difference. Also, reviewing my shot locations has helped me remember to rotate. I have recommended this app to my friends who have also started their own journeys!”
“I love tracking water, protein and fiber on the app. It's really cool it's able to pull my weight and steps too. Add the widget to you phone screen if you do get it, I love that.”
Learn More About CagriSema, Side Effects, and Weekly Shot Tracking
What Orforglipron Phase 3 Results Mean for Oral GLP-1s
Orforglipron Phase 3 results explained—what they mean for oral GLP-1 development, efficacy, safety, and future treatment options.
CagriSema Tracker - FAQs
CagriSema is Novo Nordisk's two-drugs-in-one-pen weight-management drug in testing. It combines cagrilintide and semaglutide in a weekly pen, rather than using one new molecule. As of July 2026, CagriSema is not FDA-approved and is not available to the public. The application went to the FDA in December 2025 on the strength of REDEFINE 1 and 2, and the late-2026 decision window you may have read about comes from Novo's guidance rather than any confirmed date. The practical answer is still trial-only. MeAgain helps with the part you can use now: tracking your current medication, side effects, food, water, and weight trend so the record is already useful if CagriSema reaches the public later.
Your Journey Back to You,
One Day at a Time
Track the plan, dose, meals, and milestones in one place that actually keeps up with your day.